NO20053783L - Behandling av godartet prostatahyperplasi - Google Patents
Behandling av godartet prostatahyperplasiInfo
- Publication number
- NO20053783L NO20053783L NO20053783A NO20053783A NO20053783L NO 20053783 L NO20053783 L NO 20053783L NO 20053783 A NO20053783 A NO 20053783A NO 20053783 A NO20053783 A NO 20053783A NO 20053783 L NO20053783 L NO 20053783L
- Authority
- NO
- Norway
- Prior art keywords
- benign prostatic
- prostatic hyperplasia
- treatment
- lonidamine
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Det beskrives en fremgangsmåte for terapi eller profylakse av benign prostatisk hyperplasi ved administrering av lonidamin eller en lonidaminanalog. Videre tilveiebringes det enhetsdoseringsformer av lonidamin eller en analog, brukbar for slik terapi eller profylakse.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44111003P | 2003-01-17 | 2003-01-17 | |
US44234403P | 2003-01-23 | 2003-01-23 | |
US45884603P | 2003-03-28 | 2003-03-28 | |
US45866303P | 2003-03-28 | 2003-03-28 | |
US45866503P | 2003-03-28 | 2003-03-28 | |
US46001203P | 2003-04-02 | 2003-04-02 | |
US47290703P | 2003-05-22 | 2003-05-22 | |
US48826503P | 2003-07-18 | 2003-07-18 | |
US49616303P | 2003-08-18 | 2003-08-18 | |
PCT/US2004/001141 WO2004064735A2 (en) | 2003-01-17 | 2004-01-16 | Treatment of benign prostatic hyperplasia |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053783D0 NO20053783D0 (no) | 2005-08-09 |
NO20053783L true NO20053783L (no) | 2005-09-27 |
Family
ID=32777423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053783A NO20053783L (no) | 2003-01-17 | 2005-08-09 | Behandling av godartet prostatahyperplasi |
Country Status (13)
Country | Link |
---|---|
US (4) | US6989400B2 (no) |
EP (2) | EP1610778A4 (no) |
JP (2) | JP2006518343A (no) |
KR (2) | KR20050098249A (no) |
AU (2) | AU2004206870A1 (no) |
BR (1) | BRPI0406796A (no) |
CA (2) | CA2513572A1 (no) |
DE (1) | DE04702967T1 (no) |
ES (1) | ES2254046T1 (no) |
IL (1) | IL169685A0 (no) |
MX (2) | MXPA05007571A (no) |
NO (1) | NO20053783L (no) |
WO (2) | WO2004064735A2 (no) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795227B2 (en) | 2004-06-17 | 2010-09-14 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
US7524885B2 (en) * | 2002-04-01 | 2009-04-28 | The Governors Of The University Of Alberta | Compounds that stimulate glucose utilization and methods of use |
MXPA05007571A (es) | 2003-01-17 | 2005-11-17 | Threshold Pharmaceuticals Inc | Tratamiento para hiperplasia protatica benigna utilizando agentes energoliticos. |
WO2006091790A1 (en) | 2005-02-23 | 2006-08-31 | Xenoport, Inc. | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use |
US20060287253A1 (en) * | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
US8324175B2 (en) * | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
EP1986660A4 (en) * | 2006-02-24 | 2009-08-26 | Univ Texas | HEXOSE-BASED COMPOUNDS FOR TREATING CANCER |
MX2008011127A (es) | 2006-03-02 | 2008-10-31 | Astellas Pharma Inc | INHIBIDOR DE 17ß HSD TIPO 5. |
US20100203110A1 (en) * | 2006-12-18 | 2010-08-12 | The Johns Hopkins University | Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production |
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
MX2010000918A (es) | 2007-07-24 | 2010-03-15 | Astellas Pharma Inc | Derivado de bencimidazol. |
ES2392120T3 (es) | 2007-08-31 | 2012-12-04 | Astellas Pharma Inc. | Derivado de piperidina |
US8603123B2 (en) | 2008-04-28 | 2013-12-10 | Urotech, Inc. | Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration |
US9492417B2 (en) * | 2008-08-21 | 2016-11-15 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
CA3024263A1 (en) * | 2009-01-29 | 2010-08-05 | Young Hee Ko | Compositions and methods for the treatment of cancer |
WO2013153821A1 (ja) * | 2012-04-12 | 2013-10-17 | Omura Satoshi | Pdk4阻害剤及びその利用 |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
JP6552509B2 (ja) | 2014-01-14 | 2019-07-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 選択的atp阻害剤をカプセル化するシクロデキストリン組成物およびその使用 |
US10751306B2 (en) | 2015-11-06 | 2020-08-25 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
EP3564214A1 (en) | 2018-05-04 | 2019-11-06 | Universita' Degli Studi G. D Annunzio Chieti - Pescara | Indazole derivatives as modulators of the cannabinoid system |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1052111B (it) * | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
US4684627A (en) | 1981-09-08 | 1987-08-04 | Leveen Harry H | Treatment of cancer with phlorizin and its derivatives |
CA1289077C (en) | 1984-08-13 | 1991-09-17 | Harry H. Leveen | Treatment of cancer with phlorizin and its derivatives |
US5260327A (en) * | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
AU1893492A (en) * | 1991-04-17 | 1992-11-17 | Merck & Co., Inc. | Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor |
US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
US5654320A (en) * | 1995-03-16 | 1997-08-05 | Eli Lilly And Company | Indazolecarboxamides |
CA2223081C (en) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
FR2737721B1 (fr) | 1995-08-08 | 1997-09-05 | Roussel Uclaf | Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant |
JPH10511699A (ja) | 1995-10-18 | 1998-11-10 | カノルト アルツナイミッテル ゲー エム ベー ハー | リグナン及びその製造方法並びに医薬組成物及びその使用方法 |
DE19621319A1 (de) | 1996-05-28 | 1997-12-04 | Hoechst Ag | Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US6054432A (en) | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
IT1289938B1 (it) | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
IT1289939B1 (it) | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua |
CN1078462C (zh) * | 1997-07-09 | 2002-01-30 | 辛国芳 | 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用 |
US6482802B1 (en) * | 1998-05-11 | 2002-11-19 | Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6001865A (en) * | 1999-05-04 | 1999-12-14 | Angelini Pharmaceuticals Inc. | 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents |
MXPA05007571A (es) | 2003-01-17 | 2005-11-17 | Threshold Pharmaceuticals Inc | Tratamiento para hiperplasia protatica benigna utilizando agentes energoliticos. |
CA2561303C (en) * | 2004-03-25 | 2011-01-18 | The Regents Of The University Of Michigan | Gossypol co-crystals and the use thereof |
-
2004
- 2004-01-16 MX MXPA05007571A patent/MXPA05007571A/es unknown
- 2004-01-16 ES ES04702967T patent/ES2254046T1/es active Pending
- 2004-01-16 AU AU2004206870A patent/AU2004206870A1/en not_active Abandoned
- 2004-01-16 WO PCT/US2004/001141 patent/WO2004064735A2/en not_active Application Discontinuation
- 2004-01-16 KR KR1020057013198A patent/KR20050098249A/ko not_active Application Discontinuation
- 2004-01-16 EP EP04702967A patent/EP1610778A4/en not_active Withdrawn
- 2004-01-16 CA CA002513572A patent/CA2513572A1/en not_active Abandoned
- 2004-01-16 AU AU2004206869A patent/AU2004206869A1/en not_active Abandoned
- 2004-01-16 WO PCT/US2004/001146 patent/WO2004064736A2/en not_active Application Discontinuation
- 2004-01-16 MX MXPA05007572A patent/MXPA05007572A/es unknown
- 2004-01-16 JP JP2006500983A patent/JP2006518343A/ja not_active Withdrawn
- 2004-01-16 KR KR1020057013200A patent/KR20050098250A/ko not_active Application Discontinuation
- 2004-01-16 US US10/759,337 patent/US6989400B2/en not_active Expired - Fee Related
- 2004-01-16 BR BR0406796-7A patent/BRPI0406796A/pt not_active Application Discontinuation
- 2004-01-16 EP EP04702976A patent/EP1592430A4/en not_active Withdrawn
- 2004-01-16 JP JP2006500981A patent/JP2006516571A/ja active Pending
- 2004-01-16 DE DE04702967T patent/DE04702967T1/de active Pending
- 2004-01-16 CA CA002513575A patent/CA2513575A1/en not_active Abandoned
-
2005
- 2005-06-29 US US11/172,050 patent/US20050271723A1/en not_active Abandoned
- 2005-06-29 US US11/171,020 patent/US20050272795A1/en not_active Abandoned
- 2005-06-29 US US11/171,138 patent/US20050272796A1/en not_active Abandoned
- 2005-07-14 IL IL169685A patent/IL169685A0/en unknown
- 2005-08-09 NO NO20053783A patent/NO20053783L/no unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795227B2 (en) | 2004-06-17 | 2010-09-14 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1610778A2 (en) | 2006-01-04 |
JP2006516571A (ja) | 2006-07-06 |
KR20050098249A (ko) | 2005-10-11 |
US20040167196A1 (en) | 2004-08-26 |
NO20053783D0 (no) | 2005-08-09 |
EP1592430A4 (en) | 2006-05-31 |
WO2004064735A3 (en) | 2004-12-16 |
US20050272795A1 (en) | 2005-12-08 |
US20050272796A1 (en) | 2005-12-08 |
US6989400B2 (en) | 2006-01-24 |
CA2513572A1 (en) | 2004-08-05 |
AU2004206870A1 (en) | 2004-08-05 |
CA2513575A1 (en) | 2004-08-05 |
KR20050098250A (ko) | 2005-10-11 |
AU2004206869A1 (en) | 2004-08-05 |
WO2004064735A2 (en) | 2004-08-05 |
BRPI0406796A (pt) | 2006-01-17 |
WO2004064736A2 (en) | 2004-08-05 |
DE04702967T1 (de) | 2006-06-22 |
US20050271723A1 (en) | 2005-12-08 |
ES2254046T1 (es) | 2006-06-16 |
IL169685A0 (en) | 2007-07-04 |
JP2006518343A (ja) | 2006-08-10 |
MXPA05007571A (es) | 2005-11-17 |
WO2004064736A3 (en) | 2005-05-06 |
MXPA05007572A (es) | 2005-11-17 |
EP1592430A2 (en) | 2005-11-09 |
EP1610778A4 (en) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053783L (no) | Behandling av godartet prostatahyperplasi | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
NO20034204D0 (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
NO20051692L (no) | Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt | |
NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
NO20053042L (no) | Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi. | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
EA200401043A1 (ru) | Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm ) | |
AU2002360592A1 (en) | Inhibitors of hepatitis c virus | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
NO20014986D0 (no) | 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer | |
NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
NO20030381L (no) | Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser | |
PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
HUP0000558A2 (hu) | Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
NO20076616L (no) | 17beta-HSD1- og STS-inhibitorer | |
NO20045354L (no) | Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser | |
CY1106319T1 (el) | Τοπικη θepαπεια στη μασταλγια | |
NO951498L (no) | Farmasöytisk preparat for behandling av osteoporose | |
NO20051168L (no) | Anvendelse av fermentert hvetekimekstrakt som anti-inflammasjonsmiddel | |
ATE451934T1 (de) | Pharmazeutische zusammensetzung zur behandlung von rhinitiden | |
BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser |